Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: Exploratory study using primary and paired metastatic lesions

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  Inari, Hitoshi ^a   Suganuma, Nobuyasu ^a   Kawachi, Kae ^a   Yoshida, Tatsuya ^a   Yamanaka, Takashi ^a   Nakamura, Yoshiyasu ^a   Yoshihara, Mitsuyo ^a   Nakayama, Hirotaka ^b   Yamanaka, Ayumi ^b   Masudo, Katsuhiko ^b   Oshima, Takashi ^b   Yokose, Tomoyuki ^a   Rino, Yasushi ^b   Shimizu, Satoru ^a   Miyagi, Yohei ^a   Masuda, Munetaka ^b  

^a KANAGAWA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Epigenetics; EZH2; Immunohistochemistry; Ki 67; Metastatic breast cancer; Prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER; EZH2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENOPAUSE; METASTATIC BREAST CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIMARY TUMOR; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR BIOPSY; TUMOR VOLUME; BIOPSY; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR RECURRENCE; UPREGULATION;

ADULT; BIOPSY; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 85014127099     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-017-3154-3     Document Type: Article

References (39)

1. Kobayashi T. From improved survival to potential cure in patients with metastatic breast cancer. Breast Cancer. 2012;19(3):187-90. doi: 10.1007/s12282-011-0307-0.
2. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol. 2002;20(3):620-3.
3. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197-205.
4. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer. 1999;85:104-11.
5. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974-84.
6. NCCN.org. (2016) NCCN clinical practice guidelines in oncology: breast cancer. Ver. 1. http://nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 2 Jan 2016
7. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25:1871-88. doi: 10.1093/annonc/mdu385.
8. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20(12):1953-8. doi: 10.1093/annonc/mdp263.
9. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20(9):1499-504. doi: 10.1093/annonc/mdp028.
10. Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS). Breast Cancer Res. 2010;12(6):R92. doi: 10.1186/bcr2771.
11. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30(6):587-92. doi: 10.1200/JCO.2010.33.5232.
12. Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011;9:131. doi: 10.1186/1477-7819-9-131.
13. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039-43.
14. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell. 2007;128:735-45.
15. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006;441:349-53.
16. Levine SS, Weiss A, Erdjument-Bromage H, Shao Z, Tempst P, Kingston RE. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol. 2002;22:6070-8.
17. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100:11606-11.
18. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24:268-73.
19. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene. 2009;28:843-53. doi: 10.1038/onc.2008.433.
20. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27:7274-84. doi: 10.1038/onc.2008.333.
21. Zeidler M, Varambally S, Cao Q, Chinnaiyan AM, Ferguson DO, Merajver SD, et al. The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia. 2005;7:1011-9.
22. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell. 2011;19:86-100. doi: 10.1016/j.ccr.2010.10.035.
23. Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, et al. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res. 2011;71:2360-70. doi: 10.1158/0008-5472.CAN-10-1933.
24. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003;22:5323-35.
25. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997-4013. doi: 10.1200/JCO.2013.50.9984.
26. Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res. 2011;13(5):R87. doi: 10.1186/bcr2944.
27. Kiba T, Inamoto T, Nishimura T, Ueno M, Yanagihara K, Teramukai S, et al. The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery. BMC Cancer. 2008;8:323. doi: 10.1186/1471-2407-8-323.
28. Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, et al. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol. 2012;43:1638-44. doi: 10.1016/j.humpath.2011.12.004.
29. Reijm EA, Timmermans AM, Look MP, Meijer-van Gelder ME, Stobbe CK, van Deurzen CH, et al. High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann Oncol. 2014;25(11):2185-90. doi: 10.1093/annonc/mdu391. Epub 2014 Sep 5.
30. Fluge Ø, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, Lilleng R, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer. 2009;101(8):1282-9. doi: 10.1038/sj.bjc.6605333.
31. Changchien YC, Tátrai P, Papp G, Sápi J, Fónyad L, Szendroi M, et al. Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2). J Transl Med. 2012;10:216. doi: 10.1186/1479-5876-10-216.
32. Reijm EA, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, van Gelder ME, et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat. 2011;125:387-94. doi: 10.1007/s10549-010-0836-9.
33. Sato T, Kaneda A, Tsuji S, Isagawa T, Yamamoto S, Fujita T, et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep. 2013;3:1911. doi: 10.1038/srep01911.
34. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110:7922-7. doi: 10.1073/pnas.1303800110.
35. Epizyme®, Inc. (2013). Epizyme® is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. http://epizyme.com. Accessed 20 Dec 2015
36. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008;14:8019-26.
37. Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer. 2010;17:269-75. doi: 10.1007/s12282-009-0161-5.
38. Tanei T, Shimomura A, Shimazu K, Nakayama T, Kim SJ, Iwamoto T, et al. Prognostic significance of Ki67 expression after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol. 2011;37:155-61. doi: 10.1016/j.ejso.2010.10.009.
39. Hitoshi I, Nobuyasu S, Kae K, Tatsuya Y, Hirotaka N, Takashi Y, et al. Correlation of expression of enhancer of zeste homolog 2 with the survival outcome in patients with metastatic breast cancer using primary and paired metastatic lesions. J Clin Oncol. 2016;34:e23227.